---
title: 'Funding Daily Summary: What Happened on November 12, 2026'
headline: Blackstone offers Pfizer up to $1.5 billion for berobenatide development
description: Neurosterix raised $105 million for its schizophrenia program. Orakl
  Oncology raised $34 million, while Novo committed $200 million to the World Diabetes
  Federation.
url: https://thebench.bio/news/funding/2026-11-12
topic: funding
date: '2026-11-12'
covers:
- '2026-11-12'
date_published: '2026-11-12T12:01:52Z'
date_modified: '2026-11-13T00:01:44Z'
tags:
- Funding
- Industry
- Clinical
- Software
sources: 9
publisher: TheBench.Bio
---

# Funding Daily Summary: What Happened on November 12, 2026

**Blackstone offers Pfizer up to $1.5 billion for berobenatide development**

Neurosterix raised $105 million for its schizophrenia program. Orakl Oncology raised $34 million, while Novo committed $200 million to the World Diabetes Federation.

## Today in brief

Blackstone Life Sciences agreed to cover up to $1.5 billion of Pfizer’s berobenatide development costs through 2028, with potential payments tied to US approval and sales milestones. [1] [2] [3] Neurosterix raised $105 million to move its schizophrenia candidate NTX-253 toward Phase 2. [4]

Orakl Oncology secured $34 million to expand its AI platform for predicting cancer drug responses. [5] Novo committed $200 million to support the World Diabetes Federation. [6]

## Blackstone will cover up to $1.5 billion of Pfizer’s berobenatide costs

Blackstone Life Sciences agreed to fund up to $1.5 billion of development costs for Pfizer’s investigational monthly GLP-1 drug berobenatide through 2028. [1] [2] [3] Blackstone may receive milestone payments if the drug wins US approval for chronic weight management and meets specified sales targets. [1] [2] [3]

Pfizer retains control of the program and its decisions, while Blackstone gets no ownership or rights to the drug. [1] [2] [3] In a Phase 2b study, monthly berobenatide produced up to 12.3% greater weight loss than placebo at 28 weeks. [2] [7] [8]

Pfizer plans 10 ongoing or planned Phase 3 berobenatide studies as part of a broader program of more than 20 trials for obesity and related conditions in 2026. [1] [2] [3] [7]

## Neurosterix raises $105 million for schizophrenia drug

Neurosterix raised $105 million in a Series B led by RTW Investments to advance NTX-253, its oral schizophrenia candidate, toward Phase 2. [4] NTX-253 is a positive allosteric modulator of the muscarinic M4 receptor, designed to amplify the receptor’s response to acetylcholine. [4]

Neurosterix said it completed Phase 1 studies in healthy volunteers and people with stable schizophrenia in October. [4] The company said the studies support once-daily oral dosing, but NTX-253’s clinical efficacy has not been demonstrated. [4]

Neurosterix plans to start Phase 2 but has not set a date. [4] It is also developing NTX-819 for mood and anxiety disorders and NTX-529 for other psychosis- and mood-related uses. [4]

## Also worth knowing

- Orakl Oncology raised $34 million in a Series A to expand its platform, which combines patient-derived tumor models and AI to predict cancer drug responses. [5]
- Novo committed $200 million to support the World Diabetes Federation. [6]
- Johnson & Johnson led an investment in Francis Medical to support development of its prostate-cancer water-vapor therapy device. [9]

## The day in numbers

- **Up to $1.5 billion**: Maximum Blackstone funding for Pfizer’s berobenatide development through 2028. [1] [2] [3]
- **$105 million**: Neurosterix’s Series B financing for its pipeline, including NTX-253. [4]
- **$34 million**: Orakl Oncology’s Series A financing. [5]
- **$200 million**: Novo’s commitment to support the World Diabetes Federation. [6]

## Also published

- [Blackstone bets $1.5B on Pfizer’s obesity drug](<https://www.biopharmadive.com/news/blackstone-pfizer-berobenatide-deal/874483/>), BioPharma Dive
- [How Nasdaq became biotech’s default exchange — and why the IPO comeback is testing its value](<https://www.pharmavoice.com/news/why-biotech-companies-list-on-nasdaq/874486/>), PharmaVoice
- [Blackstone backs Pfizer’s obesity ambitions with $1.5bn fund](<https://www.pharmaceutical-technology.com/news/blackstone-backs-pfizers-obesity-ambitions-with-1-5bn-fund/>), Pharmaceutical Technology
- [Blackstone buys into Pfizer's GLP-1 drug development](<https://pharmaphorum.com/news/blackstone-buys-pfizers-glp-1-drug-development>), pharmaphorum

## Sources

1. [Pfizer and Blackstone Sign Co-Funding Deal for berobenatide](<https://www.pharmexec.com/view/pfizer-blackstone-sign-co-funding-deal-berobenatide>), Pharmaceutical Executive, 2026-11-12
2. [Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development](<https://www.biopharminternational.com/view/blackstone-to-provide-pfizer-up-to-1-5-billion-for-monthly-glp-1-berobenatide-development>), BioPharm International, 2026-11-12
3. [Pfizer Deal With Blackstone Secures Up to $1.5B to Bankroll GLP-1 Drug Trials](<https://medcitynews.com/2026/11/pfizer-blackstone-life-sciences-long-acting-glp-1-berobenatide-metabolic-obesity-weight-management-pfe/>), MedCity News, 2026-11-12
4. [Addex spinout Neurosterix raises $105M to advance schizophrenia drug into Phase 2](<https://european-biotechnology.com/latest-news/addex-spinout-neurosterix-raises-105m-to-advance-schizophrenia-drug-into-phase-2/>), European Biotechnology, 2026-11-12
5. [Orakl raises $34M to scale AI platform predicting cancer drug responses](<https://european-biotechnology.com/latest-news/orakl-raises-34m-to-scale-ai-platform-predicting-cancer-drug-responses/>), European Biotechnology, 2026-11-12
6. [Novo commits $200m to support World Diabetes Federation](<https://pharmaphorum.com/news/novo-commits-200m-support-world-diabetes-federation>), pharmaphorum, 2026-11-12
7. [The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA](<https://www.biopharminternational.com/view/the-biopharm-brief-an-ai-designed-multibody-adc-enters-the-clinic-blackstone-backs-pfizer-s-monthly-glp-1-and-engene-readies-a-bladder-cancer-bla>), BioPharm International, 2026-11-12
8. [Pharmaceutical Executive Daily: Moderna Outlines Growth Plan at 2026 Analyst Day](<https://www.pharmexec.com/view/daily-moderna-outlines-growth-plan-2026-analyst-day>), Pharmaceutical Executive, 2026-11-12
9. [J&J leads Francis Medical investment to fund prostate cancer device](<https://www.medtechdive.com/news/jj-leads-francis-medical-investment-to-fund-prostate-cancer-device/874352/>), MedTech Dive, 2026-11-12

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.pharmexec.com/view/pfizer-blackstone-sign-co-funding-deal-berobenatide>
[2]: <https://www.biopharminternational.com/view/blackstone-to-provide-pfizer-up-to-1-5-billion-for-monthly-glp-1-berobenatide-development>
[3]: <https://medcitynews.com/2026/11/pfizer-blackstone-life-sciences-long-acting-glp-1-berobenatide-metabolic-obesity-weight-management-pfe/>
[4]: <https://european-biotechnology.com/latest-news/addex-spinout-neurosterix-raises-105m-to-advance-schizophrenia-drug-into-phase-2/>
[5]: <https://european-biotechnology.com/latest-news/orakl-raises-34m-to-scale-ai-platform-predicting-cancer-drug-responses/>
[6]: <https://pharmaphorum.com/news/novo-commits-200m-support-world-diabetes-federation>
[7]: <https://www.biopharminternational.com/view/the-biopharm-brief-an-ai-designed-multibody-adc-enters-the-clinic-blackstone-backs-pfizer-s-monthly-glp-1-and-engene-readies-a-bladder-cancer-bla>
[8]: <https://www.pharmexec.com/view/daily-moderna-outlines-growth-plan-2026-analyst-day>
[9]: <https://www.medtechdive.com/news/jj-leads-francis-medical-investment-to-fund-prostate-cancer-device/874352/>
